| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 27.15M | 27.04M | 20.35M | 27.66M | 20.51M | 7.58M |
| Gross Profit | 14.93M | 13.27M | 5.98M | 9.65M | 3.96M | 2.51M |
| EBITDA | -38.04M | -50.32M | -54.38M | -52.09M | -73.12M | -29.71M |
| Net Income | -38.61M | -42.75M | -59.43M | -62.19M | -76.76M | -29.45M |
Balance Sheet | ||||||
| Total Assets | 108.33M | 118.88M | 96.39M | 119.19M | 100.77M | 35.41M |
| Cash, Cash Equivalents and Short-Term Investments | 22.17M | 28.46M | 36.80M | 49.36M | 35.81M | 28.59M |
| Total Debt | 31.62M | 30.19M | 29.54M | 28.05M | 287.00K | 532.00K |
| Total Liabilities | 44.34M | 46.87M | 38.24M | 39.19M | 15.22M | 7.26M |
| Stockholders Equity | 63.99M | 72.02M | 58.14M | 80.00M | 85.55M | 28.15M |
Cash Flow | ||||||
| Free Cash Flow | -26.92M | -38.70M | -30.96M | -48.42M | -50.67M | -17.85M |
| Operating Cash Flow | -26.79M | -38.56M | -30.38M | -47.84M | -50.41M | -17.74M |
| Investing Cash Flow | -128.00K | -8.93M | -547.00K | -573.00K | -8.13M | -1.62M |
| Financing Cash Flow | 25.26M | 38.53M | 18.25M | 61.94M | 65.77M | 27.55M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $33.28M | -16.99 | -14.76% | ― | 27.05% | 55.03% | |
54 Neutral | $109.58M | -0.81 | -55.06% | ― | 41.79% | 18.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $52.90M | ― | ― | ― | 35.10% | 39.15% | |
41 Neutral | $48.10M | -0.52 | -48.46% | ― | 0.85% | 29.83% | |
41 Neutral | $53.84M | -1.20 | -219.68% | ― | 25.70% | 39.25% | |
38 Underperform | $9.26M | ― | -186.64% | ― | -1.90% | 87.72% |
On September 25, 2025, DarioHealth Corp. filed an Amended and Restated Certificate of Designation for its Series C-1 Preferred Stock to accelerate the mandatory conversion of shares into common stock or pre-funded warrants, ensuring holders receive accrued dividends. Additionally, the company announced a strategic review to maximize shareholder value, considering opportunities such as a sale or merger. Earlier, on September 22, 2025, DarioHealth announced a $17.5 million private placement of common stock to fund general corporate purposes.
The most recent analyst rating on (DRIO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on DarioHealth stock, see the DRIO Stock Forecast page.
On September 18, 2025, DarioHealth Corp. amended and restated the certificates of designation for its Series A-1, Series C, and Series D preferred stocks. These changes were made to accelerate the mandatory conversion of preferred shares into common stock or pre-funded warrants, allowing holders to receive accrued dividends as well. This strategic move is expected to streamline the company’s capital structure without issuing new securities.
The most recent analyst rating on (DRIO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on DarioHealth stock, see the DRIO Stock Forecast page.
DarioHealth Corp. announced that it has regained compliance with the Nasdaq’s minimum bid price requirement as of September 12, 2025. This development follows a period of non-compliance starting September 16, 2024, and signifies a positive turn for the company’s stock market standing, potentially stabilizing its position and reassuring stakeholders.
The most recent analyst rating on (DRIO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on DarioHealth stock, see the DRIO Stock Forecast page.
DarioHealth’s recent earnings call paints a picture of a company navigating both challenges and opportunities. The sentiment expressed during the call was cautiously optimistic, highlighting strong client acquisition, improved gross margins, and strategic partnerships as positive indicators for future growth. However, the company also faces hurdles such as revenue decline, delayed cash flow breakeven, and the loss of a significant contract. Despite these challenges, DarioHealth’s strategic focus on AI and operational efficiency suggests a promising path to recovery and growth.
On August 25, 2025, DarioHealth Corp. announced a 20-to-1 reverse stock split of its common stock, which will take effect on August 28, 2025. This move, approved by the board and stockholders, reduces the number of outstanding shares significantly while maintaining the same authorized shares and stockholder voting power. The reverse split aims to consolidate shares without affecting the proportional rights of stockholders, and it reflects the company’s strategic financial adjustments in the digital health market.
The most recent analyst rating on (DRIO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on DarioHealth stock, see the DRIO Stock Forecast page.
DarioHealth Corp. is a global digital therapeutics company that provides personalized health interventions through precision data analytics, software, and coaching, focusing on chronic conditions such as diabetes and hypertension. In its latest earnings report, DarioHealth reported a decrease in total revenues to $12.1 million for the first half of 2025, compared to $12 million in the same period of 2024. The company’s net loss widened to $22.2 million from $20.8 million in the previous year, reflecting increased financial expenses and operating costs. Key financial metrics showed a decline in cash and cash equivalents to $21.9 million from $27.8 million at the end of 2024, alongside a reduction in total assets. Despite these challenges, DarioHealth continues to focus on expanding its digital health solutions and partnerships. Looking forward, the company aims to enhance its market presence and achieve profitability through strategic initiatives and product development, although it remains dependent on securing additional funding to support its operations.